New dose sched­ule for J&J bis­pe­cif­ic; Lay­offs at Ring Ther­a­peu­tics; Re­gen­eron’s pri­or­i­ty re­view

Plus, news about En­ver­ic Bio­sciences and Kazia Ther­a­peu­tics:

John­son & John­son’s bis­pe­cif­ic gets a new dos­ing sched­ule: The FDA ap­proved a re­duced dos­ing reg­i­men for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER